Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study developed a deep-learning model that accurately diagnosed alopecia areata with an accuracy of 88.92% and distinguished its activity levels with an accuracy of 83.33%, highlighting the potential for artificial intelligence in improving the diagnosis and treatment of this autoimmune hair loss condition.

This research outlines a protocol for a systematic review to map the evidence on alopecia areata in Sub-Saharan Africa, aiming to identify research gaps and guide future studies and policy decisions related to this condition in the region.

In this study, both methotrexate gel and betamethasone lotion were found to be effective and safe treatments for localized alopecia areata, with similar overall response rates. However, methotrexate gel had a higher incidence of local side effects, such as irritant dermatitis and itching.

This study found a bidirectional causal association between major depression disorder and alopecia areata, but no association between mental disorders and androgenetic alopecia, suggesting a focus on mental health strategies for alopecia areata management.

This article proposes renaming frontal fibrosing alopecia to frontal fibrosing alopecia syndrome to better reflect its varied presentations and enhance understanding and treatment approaches.

In this 10-year study at a single hair referral center, pattern hair loss was the most common type of alopecia, affecting 67% of patients.

This study found that the global prevalence of alopecia areata is estimated at 1.93%, affecting around 15.05 million people, with significant regional and demographic variations.

In this study, DNA analysis of patients with androgenetic alopecia and alopecia areata indicated potential differences in treatment response based on genetic makeup across Romanian and Brazilian populations, notably involving genes like GR-alpha and SULT1A1, which may guide personalized treatment strategies.

In this case report, the authors describe a rare presentation of alopecia areata mimicking frontal fibrosing alopecia, emphasizing the diagnostic value of trichoscopy and the need to consider alopecia areata in differential diagnoses.

This article discusses the association of stressful life events with alopecia areata and their effects on patients' psychosocial outcomes, but it reports no new empirical findings.

This study found that drug-induced alopecia areata was most commonly associated with TNF-alpha inhibitors and dupilumab, with most cases improving after discontinuing the medication.

This study suggests that the emulsion extract of brevilin A from Centipeda minima may stimulate hair regrowth in individuals with mild to moderate vertex balding by inhibiting JAK3.

This study found that 79% of adolescents with moderate-to-severe alopecia areata treated with baricitinib experienced significant scalp hair regrowth, although further research is needed to confirm these results.

This review synthesizes current evidence on alopecia areata, detailing its clinical features, pathogenesis, and treatment options, but does not present new clinical results.

This systematic review of pulse corticosteroid therapy for alopecia areata found relatively low complete response rates, but responders experienced low relapse rates, indicating potential benefits for patients with favorable prognostic factors.

This study found that topical corticosteroids are the most supported first-line treatment for pediatric alopecia areata, with contact immunotherapy as the next best option.

This review outlines the historical and ongoing evolution in understanding and treating alopecia areata, highlighting current research frontiers in genetics, immune mechanisms, and potential new treatments, but reports no new results.

In this study, activation of Tgr5 was found to improve alopecia areata and bone microstructure in mice by down-regulating the JAK1-STAT3 signaling pathway.

This review discusses current and emerging therapies for alopecia areata, highlights the challenges in managing this chronic disease, and emphasizes the importance of addressing its psychosocial impacts; it reports no new clinical results.

In this overview, the authors note that both pharmacologic and nonpharmacologic treatments are effective for pattern hair loss, emphasizing early detection and intervention to maintain hair.

This study introduced a non-invasive, three-step diagnostic algorithm for alopecia that combines clinical and trichoscopic features to accurately identify alopecia subtypes, potentially reducing reliance on invasive histopathology.

The study reported that from 2016 to 2020, the number of patients with alopecia areata in Taiwan increased, with severe cases utilizing more systemic therapies and having higher outpatient visits than mild/moderate cases.

This study offers genetic evidence supporting a causal relationship between thyroid dysfunction and alopecia areata, which may help in managing and treating AA patients.

This review discusses current and emerging therapies for alopecia areata, highlighting unmet therapeutic needs and the psychosocial burden on patients but reports no new clinical results.

This source presents an expert consensus framework for determining which Australian patients with alopecia areata should receive subsidized JAK inhibitor therapy, emphasizing the need for future research including patient perspectives to enhance criteria, ensure fair treatment access, and evaluate real-world outcomes.

This case study reported on a 30-year-old male with autoimmune polyglandular syndrome type 2, highlighting rare co-occurrence with alopecia universalis and emphasizing the importance of recognizing non-endocrine symptoms for early diagnosis and management of autoimmune endocrinopathies.

In this nonrandomized controlled study, topical betamethasone dipropionate lotion was found to be significantly more effective for hair regrowth in patients with alopecia areata compared to topical minoxidil solution, with 74% showing efficacy versus 42%, respectively.

In this case report, the authors describe a rare association of alopecia universalis with frequently relapsing nephrotic syndrome in a 3-year-old girl, suggesting a possible genetic and immune-related cause, and note that tofacitinib treatment was ineffective in her case.

In this study, researchers evaluated the stability and color changes of compounded minoxidil formulations used for alopecia, finding that while the formulations remained chemically and microbiologically stable for up to 380 days, significant color changes were observed, which likely do not affect the product's effectiveness.

In this study, researchers examined the prevalence of comorbid conditions among 402 alopecia areata patients, finding that hypothyroidism was notably more frequent in women, while hyperlipidemia was more common in men, with overall thyroid function testing suggested for these patients.